ArticleInternational journal of ophthalmology2026

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy.

Jung Yeon Joo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.